TGP-377/421

• CAT Number: I043577
• CAS Number: 16752-89-9
• Molecular Formula: C20H16N6
• Molecular Weight: 340.38
• Purity: ≥95%
• Synonyms: 2-[3-(6-amino-1H-benzimidazol-2-yl)phenyl]-3H-benzimidazol-5-amine
• InChI: InChI=1S/C20H16N6/c21-13-4-6-15-17(9-13)25-19(23-15)11-2-1-3-12(8-11)20-24-16-7-5-14(22)10-18(16)26-20/h1-10H,21-22H2,(H,23,25)(H,24,26)
• InChIKey: AQEJANNNADGRSY-UHFFFAOYSA-N
• SMILES: C1=CC(=CC(=C1)C2=NC3=C(N2)C=C(C=C3)N)C4=NC5=C(N4)C=C(C=C5)N

TGP-377/421（Cat No.:I043577）is a dual-target small-molecule compound designed to inhibit key signaling pathways involved in cancer progression and immune regulation. It targets both the MAPK and PI3K/Akt/mTOR pathways, which are frequently dysregulated in various cancers, leading to enhanced tumor growth and survival. By blocking these critical pathways, TGP-377/421 aims to reduce cancer cell proliferation, increase apoptosis, and potentially overcome resistance to other treatments. Preclinical studies have shown promising results, and ongoing research is focused on evaluating its safety, efficacy, and potential use in combination therapies for solid tumors and hematological cancers.